Your browser doesn't support javascript.
Anti-SARS-CoV-2 receptor-binding domain antibody evolution after mRNA vaccination.
Cho, Alice; Muecksch, Frauke; Schaefer-Babajew, Dennis; Wang, Zijun; Finkin, Shlomo; Gaebler, Christian; Ramos, Victor; Cipolla, Melissa; Mendoza, Pilar; Agudelo, Marianna; Bednarski, Eva; DaSilva, Justin; Shimeliovich, Irina; Dizon, Juan; Daga, Mridushi; Millard, Katrina G; Turroja, Martina; Schmidt, Fabian; Zhang, Fengwen; Tanfous, Tarek Ben; Jankovic, Mila; Oliveria, Thiago Y; Gazumyan, Anna; Caskey, Marina; Bieniasz, Paul D; Hatziioannou, Theodora; Nussenzweig, Michel C.
  • Cho A; Laboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.
  • Muecksch F; Laboratory of Retrovirology, The Rockefeller University, New York, NY, USA.
  • Schaefer-Babajew D; Laboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.
  • Wang Z; Laboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.
  • Finkin S; Laboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.
  • Gaebler C; Laboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.
  • Ramos V; Laboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.
  • Cipolla M; Laboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.
  • Mendoza P; Laboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.
  • Agudelo M; Laboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.
  • Bednarski E; Laboratory of Retrovirology, The Rockefeller University, New York, NY, USA.
  • DaSilva J; Laboratory of Retrovirology, The Rockefeller University, New York, NY, USA.
  • Shimeliovich I; Laboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.
  • Dizon J; Laboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.
  • Daga M; Laboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.
  • Millard KG; Laboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.
  • Turroja M; Laboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.
  • Schmidt F; Laboratory of Retrovirology, The Rockefeller University, New York, NY, USA.
  • Zhang F; Laboratory of Retrovirology, The Rockefeller University, New York, NY, USA.
  • Tanfous TB; Laboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.
  • Jankovic M; Laboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.
  • Oliveria TY; Laboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.
  • Gazumyan A; Laboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.
  • Caskey M; Laboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA. mcaskey@rockefeller.edu.
  • Bieniasz PD; Laboratory of Retrovirology, The Rockefeller University, New York, NY, USA. pbieniasz@rockefeller.edu.
  • Hatziioannou T; Howard Hughes Medical Institute, New York, NY, USA. pbieniasz@rockefeller.edu.
  • Nussenzweig MC; Laboratory of Retrovirology, The Rockefeller University, New York, NY, USA. thatziio@rockefeller.edu.
Nature ; 600(7889): 517-522, 2021 12.
Article in English | MEDLINE | ID: covidwho-1454790
Preprint
This scientific journal article is probably based on a previously available preprint. It has been identified through a machine matching algorithm, human confirmation is still pending.
See preprint
ABSTRACT
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection produces B cell responses that continue to evolve for at least a year. During that time, memory B cells express increasingly broad and potent antibodies that are resistant to mutations found in variants of concern1. As a result, vaccination of coronavirus disease 2019 (COVID-19) convalescent individuals with currently available mRNA vaccines produces high levels of plasma neutralizing activity against all variants tested1,2. Here we examine memory B cell evolution five months after vaccination with either Moderna (mRNA-1273) or Pfizer-BioNTech (BNT162b2) mRNA vaccine in a cohort of SARS-CoV-2-naive individuals. Between prime and boost, memory B cells produce antibodies that evolve increased neutralizing activity, but there is no further increase in potency or breadth thereafter. Instead, memory B cells that emerge five months after vaccination of naive individuals express antibodies that are similar to those that dominate the initial response. While individual memory antibodies selected over time by natural infection have greater potency and breadth than antibodies elicited by vaccination, the overall neutralizing potency of plasma is greater following vaccination. These results suggest that boosting vaccinated individuals with currently available mRNA vaccines will increase plasma neutralizing activity but may not produce antibodies with equivalent breadth to those obtained by vaccinating convalescent individuals.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: Vaccines, Synthetic / Evolution, Molecular / Spike Glycoprotein, Coronavirus / COVID-19 Vaccines Type of study: Etiology study / Incidence study / Observational study / Randomized controlled trials / Risk factors Topics: Vaccines / Variants Limits: Adult / Aged / Female / Humans / Male / Middle aged / Young adult Language: English Journal: Nature Year: 2021 Document Type: Article Affiliation country: S41586-021-04060-7

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Vaccines, Synthetic / Evolution, Molecular / Spike Glycoprotein, Coronavirus / COVID-19 Vaccines Type of study: Etiology study / Incidence study / Observational study / Randomized controlled trials / Risk factors Topics: Vaccines / Variants Limits: Adult / Aged / Female / Humans / Male / Middle aged / Young adult Language: English Journal: Nature Year: 2021 Document Type: Article Affiliation country: S41586-021-04060-7